112 related articles for article (PubMed ID: 23780849)
21. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Sequist LV; Haber DA; Lynch TJ
Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
[No Abstract] [Full Text] [Related]
22. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
23. Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R; Subramanian J
Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
[No Abstract] [Full Text] [Related]
24. Targeting EGFR in non-small-cell lung cancer.
Doroshow JH
N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
[No Abstract] [Full Text] [Related]
25. EGFR mutations and sensitivity to gefitinib.
Rossi G; Marchioni A; Longo L
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
[No Abstract] [Full Text] [Related]
26. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Sasaki H; Endo K; Mizuno K; Yano M; Fukai I; Yamakawa Y; Fujii Y
Lung Cancer; 2006 Jan; 51(1):135-6. PubMed ID: 16314000
[No Abstract] [Full Text] [Related]
27. Assessing EGFR mutations.
Marchetti A; Felicioni L; Buttitta F
N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
[No Abstract] [Full Text] [Related]
28. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
29. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
30. Pharmacokinetics of gefitinib and erlotinib.
Levêque D
Lancet Oncol; 2011 Nov; 12(12):1093. PubMed ID: 22041538
[No Abstract] [Full Text] [Related]
31. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
32. Molecular on/off switch.
Milton DT; Riely GJ; Pao W; Miller VA; Kris MG; Heelan RT
J Clin Oncol; 2006 Oct; 24(30):4940-2. PubMed ID: 17050880
[No Abstract] [Full Text] [Related]
33. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Jänne PA
Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
[No Abstract] [Full Text] [Related]
35. Gefitinib: phoenix from the flames.
Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
[No Abstract] [Full Text] [Related]
36. Epidermal growth factor receptor mutations: a new insight.
Belani CP
Clin Lung Cancer; 2004 May; 5(6):328. PubMed ID: 15217529
[No Abstract] [Full Text] [Related]
37. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
[No Abstract] [Full Text] [Related]
38. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
39. Interstitial lung disease and gefitinib.
Lim KH; Chang YH
N Engl J Med; 2010 Oct; 363(16):1579; author reply 1579-80. PubMed ID: 20949670
[No Abstract] [Full Text] [Related]
40. Targeting targeted therapy.
Green MR
N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
